Studies related to Allergies and Methylsulfonylmethane

A Multicentered, Open-label Trial On The Safety And Efficacy Of Methylsulfonylmethane In The Treatment Of Seasonal Allergic Rhinitis

Effect Decrease
Trial Design Cohort
Trial Length 1-6 months
Number of Subjects 55
Sex Both Genders
Age Range 30-44, 45-64
Notes for this study:
Despite no alterations in plasma IgE and Histamine, MSM supplementation at 2600mg to persons with allergic rhinitus was able to reduce respiratory symptoms associated with allergies. Efficacy was present at day 7, increased at day 14, and maintained until the end of the trial at day 30.